{"entity":{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","aka":["MTAPESTRY 101"],"tldr":"A phase 1/2 trial of Anvumetostat and Docetaxel in advanced solid tumours, run by Amgen, active and no longer recruiting.","summary":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) is a phase 1/2 interventional study registered as NCT05094336 by Amgen, with 329 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Anvumetostat, Docetaxel and Comparator Anvumetostat Test Tablet.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05094336","url":"https://clinicaltrials.gov/study/NCT05094336"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["anvumetostat","docetaxel"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05094336","phase":"1/2","setting":"A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors","sponsor":"Amgen","participation":[{"nct":"NCT05094336","source":"https://clinicaltrials.gov/study/NCT05094336","fetchedAt":"2026-10-07T16:53:34.066Z","studySha256":"4d0b281f9994c9857fe1ceb4b8051cdc898c36f1a62bc547d8090a06ab2d06b2","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-28","leadSponsor":"Amgen","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"100 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":329,"enrolmentType":"ACTUAL","siteCount":75,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Canada","China","France","Germany","Hong Kong","Japan","South Korea","Switzerland","Taiwan","United Kingdom","United States"]}],"started":"2022-02-01","startedType":"actual","enrolled":329,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05094336/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}